Mera - Ethical, accurate drug development
The Mera system automates the culture, drugging, and staining of 3D tissues on a large scale, enabling real-time monitoring and modular scalability for diverse tissue types.
Projectdetails
Introduction
Using patented fluid management technologies, the Mera system has the ability to culture, drug, and stain 3D tissues on a large scale while monitoring everything in real time through a fully automated fluorescent microscope.
System Components
3D microtissues are added to a dedicated consumable bio-plate. The plate is then integrated into the main Mera system.
Chemical Introduction
A chemical cocktail can be introduced to selected wells on a plate in order to mature the cells into different tissue types such as:
- Liver
- Heart
- Neuronal
- Cancer
Fluid Management
The fluid pathway can be changed to allow the introduction of a drug or stain to batches of multiple different tissue types. The fluid can then be recirculated, replicating the conditions in the human body where organs interact with each other.
Monitoring and Scalability
The whole process can be monitored using the automated microscope in wide field or fluorescent modes. The system is modular and scalable, allowing a single unit to run up to 800 microtissues simultaneously.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.499.999 |
Totale projectbegroting | € 4.158.818 |
Tijdlijn
Startdatum | 1-10-2023 |
Einddatum | 30-9-2025 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- HOOKE BIO LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
3D screening system to cultivate tissue and automatically stimulate and quantify its mechanical propertiesThe project aims to develop the TissMec system for automated 3D human tissue creation and screening to expedite drug candidate evaluation and improve the drug development process. | ERC Proof of... | € 150.000 | 2024 | Details |
Developing the ‘μMass’ microplate: combining cell therapy and organ-on-chip to treat cancerHet project ontwikkelt een microplate voor in vitro celaggregaten en passieve flow om medicijnen en celtherapieën te testen. | Mkb-innovati... | € 256.550 | 2023 | Details |
IDEFIX Multiorgan toxicity and efficacy test platformCherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions. | EIC Transition | € 2.496.073 | 2022 | Details |
Slim labinstrument voor 3D celculturenIMcoMET onderzoekt de ontwikkeling van een kosteneffectief labinstrument voor continue, niet-destructieve metingen van fysiologische parameters in 3D-celculturen voor geneesmiddelonderzoek. | Mkb-innovati... | € 20.000 | 2021 | Details |
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
3D screening system to cultivate tissue and automatically stimulate and quantify its mechanical properties
The project aims to develop the TissMec system for automated 3D human tissue creation and screening to expedite drug candidate evaluation and improve the drug development process.
Developing the ‘μMass’ microplate: combining cell therapy and organ-on-chip to treat cancer
Het project ontwikkelt een microplate voor in vitro celaggregaten en passieve flow om medicijnen en celtherapieën te testen.
IDEFIX Multiorgan toxicity and efficacy test platform
Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.
Slim labinstrument voor 3D celculturen
IMcoMET onderzoekt de ontwikkeling van een kosteneffectief labinstrument voor continue, niet-destructieve metingen van fysiologische parameters in 3D-celculturen voor geneesmiddelonderzoek.
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment
3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy.